Design an AI-enabled software as a medical device that offers cutting-edge capabilities and earns the trust of healthcare professionals, ultimately improving patient care.
Back to team page
Yvette Granger
Managing Partner
Yvette’s background is in human factors engineering and human-system integration (HSI) research. She has designed methodologies, defined project scope, planned research activities, and supervised programs of research as well as individual research projects involving medical devices, touch screen interfaces, websites, and enterprise applications. In her most recent role, Yvette managed the Human Factors research programs for multi-million-dollar client accounts within the healthcare sector. She is a member of HFES, AAMI, and the Epsilon Mu Eta honor society. Yvette has an MS in Engineering Management with a certificate in HSI from the University of Missouri.



Bold facts
Learn more about

Something unique about you summed up in one sentence

Your favorite part of working at Bold Insight

In your spare time (or if you had spare time), you would absolutely do this:

How long have you been in the UX field?

You cannot start the day without doing this...

Your favorite city in the world is...and why?

Your ultimate celebrity dinner party guest list would include:

Long-term personal or professional goal?
Read our team’s latest bold insights
Why UX people make great strategy consultants
Learn why UX researchers excel as strategy consultants through data-driven approaches that address critical decisions and adapt to new contexts.
Global UX, mastered: The UXalliance’s 20-year collaboration story
This year marks the 20th anniversary of the UXalliance. To celebrate this milestone, we sat down with Gavin, one of the five founding members, to discuss the organization’s history, guiding principles, and the benefits it brings to clients.
Human factors testing for OTC drugs and non-prescription medical devices
As the field of human factors continues to evolve, so must our approaches to testing and study design. While the FDA’s 2013 guidance laid the groundwork for study design and methodology, recent discussions and conference presentations have prompted a shift in how we approach OTC HF testing, leading to more comprehensive and realistic assessments of these products.